All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
Join our
Treating classical Hodgkin lymphoma: Spotlight on targeted therapies
with Gilles Salles, Paul Bröckelmann, and Ann S. LaCasce
Saturday, November 2, 2024
8:50-9:50 CET
This independent educational activity is sponsored by Takeda. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The MDS Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MDS Hub cannot guarantee the accuracy of translated content. The MDS Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
During the MDS Hub Steering Committee meeting, held on October 26, 2023, Theo de Witte chaired a discussion on “How I treat” a patient with lower-risk myelodysplastic syndromes (MDS) showing signs of ESA failure, with contributions from Pierre Fenaux and Rafael Bejar.
How I treat” a patient with lower-risk MDS showing signs of ESA failure
Theo de Witte discusses the optimal timing of erythropoiesis-stimulating agent (ESA) treatment in patients with lower-risk MDS and how to optimize treatment following ESA-treatment failure, including the use of luspatercept; he highlights results from the phase III MEDALIST (NCT02631070) and COMMANDS (NCT03682536) trials. The committee also discusses the assessment of quality of life in placebo-controlled studies and the use of luspatercept as a first-line therapy over ESAs, specifically in patients with MDS and SF3B1 mutations. They also raise the need to consider the side effects of luspatercept and the cost of treatment.
Subscribe to get the best content related to MDS delivered to your inbox